Case-control study.
A total of 421 Age-Related Eye Disease Study (AREDS) subjects, of whom approximately 35 % were diagnosed with neovascular disease, 19 % were diagnosed with geographic atrophy, 16 % were diagnosed with both, 30 % were diagnosed with large drusen, and 215 were controls.
By using copy number assays available from Applied Biosystems Inc. (Carlsbad, CA), we examined 4 loci spanning CNP147 and neighboring CNP148 in an AREDS matched case-control sample set. We analyzed these data by copy number while controlling for 2 high-risk CFH variants, rs1061170 (Y402H) and rs1410996. We phased the high-risk CFH variants with CNP147 and analyzed haplotype frequencies in cases and controls. To further validate copy numbers, 6 Utah Centre D'etude du Polymorphism Humaine (CEPH) families were typed for CNP147, and the segregation was assessed.
Increased or decreased risk of AMD from genetic loci.
Having fewer than 2 copies of CNP147 was associated with an estimated 43 % reduction in odds of having AMD in this sample set (adjusted odds ratio [OR] = 0.57, P=0.006). CNP148 variation is rare in Caucasians and was not statistically significant. Common haplotypes reveal that the risk alleles for rs1061170 and rs1410996 most frequently segregate with higher copy numbers for CNP147, but not exclusively, and that 1 haplotype that carried a deletion of CNP147 was highly protective (OR = 0.25 P=1.3¡Á10?3) when compared with the reference.
In this matched subset of AREDS subjects, after adjusting for 2 known risk variants in CFH, CNP147 deletion statistically associates with diminished risk for AMD.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.